Understanding the Molecular Mechanisms Underpinning Gene by Environment Interactions in Psychiatric Disorders: The FKBP5 Model

Biological Psychiatry

Volumn 83, Issue 10, 2018, Pages 821-830

  Matosin, Natalie ^a,b   Halldorsdottir, Thorhildur ^a   Binder, Elisabeth B ^a,c  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epigenetics; FKBP5; FKBP51; Gene by environment; Psychiatric disorders; Stress

Indexed keywords

ENVIRONMENTAL FACTOR; EPIGENETIC REPRESSION; FKBP5 GENE; GENE; GENE INACTIVATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MENTAL DISEASE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; REVIEW; GENETIC EPIGENESIS; GENETICS; GENOTYPE; MENTAL STRESS; MUTATION;

FK 506 BINDING PROTEIN; TACROLIMUS BINDING PROTEIN 5;

EPIGENESIS, GENETIC; GENE-ENVIRONMENT INTERACTION; GENOTYPE; HUMANS; MENTAL DISORDERS; MUTATION; STRESS, PSYCHOLOGICAL; TACROLIMUS BINDING PROTEINS;

EID: 85044276697     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2018.01.021     Document Type: Review

References (121)

1. De Kloet, E.R., Joëls, M., Holsboer, F., Stress and the brain: From adaptation to disease. Nat Rev Neurosci 6 (2005), 463–475.
2. Grad, I., Picard, D., The glucocorticoid responses are shaped by molecular chaperones. Mol Cell Endocrinol 275 (2007), 2–12.
3. Sinars, C.R., Cheung-Flynn, J., Rimerman, R.A., Scammell, J.G., Smith, D.F., Clardy, J., Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes. Proc Natl Acad Sci U S A 100 (2003), 868–873.
4. Wochnik, G.M., Ruegg, J., Abel, G.A., Schmidt, U., Holsboer, F., Rein, T., FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem 280 (2005), 4609–4616.
5. Scammell, J.G., Denny, W.B., Valentine, D.L., Smith, D.F., Overexpression of the FK506-binding immunophilin FKBP51 is the common cause of glucocorticoid resistance in three New World primates. Gen Comp Endocrinol 124 (2001), 152–165.
6. Menke, A., Arloth, J., Putz, B., Weber, P., Klengel, T., Mehta, D., et al. Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients. Neuropsychopharmacology 37 (2012), 1455–1464.
7. Scharf, S.H., Liebl, C., Binder, E.B., Schmidt, M.V., Muller, M.B., Expression and regulation of the Fkbp5 gene in the adult mouse brain. PloS One, 6, 2011, e16883.
8. Rein, T., FK506 binding protein 51 integrates pathways of adaptation: FKBP51 shapes the reactivity to environmental change. Bioessays 38 (2016), 894–902.
9. Zannas, A.S., Wiechmann, T., Gassen, N.C., Binder, E.B., Gene-stress-epigenetic regulation of FKBP5: Clinical and translational implications. Neuropsychopharmacology 41 (2016), 261–274.
10. Binder, E.B., Salyakina, D., Lichtner, P., Wochnik, G.M., Ising, M., Putz, B., et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36 (2004), 1319–1325.
11. Klengel, T., Mehta, D., Anacker, C., Rex-Haffner, M., Pruessner, J.C., Pariante, C.M., et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci 16 (2013), 33–41.
12. Klengel, T., Binder, E.B., Allele-specific epigenetic modification: A molecular mechanism for gene-environment interactions in stress-related psychiatric disorders?. Epigenomics 5 (2013), 109–112.
13. Maner, J.K., Kenrick, D.T., When adaptations go awry: Functional and dysfunctional aspects of social anxiety. Soc Issues Policy Rev 4 (2010), 111–142.
14. VanZomeren-Dohm, A.A., Pitula, C.E., Koss, K.J., Thomas, K., Gunnar, M.R., FKBP5 moderation of depressive symptoms in peer victimized, post-institutionalized children. Psychoneuroendocrinology 51 (2015), 426–430.
15. Binder, E.B., The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 34:Suppl 1 (2009), S186–S195.
16. Buchmann, A.F., Holz, N., Boecker, R., Blomeyer, D., Rietschel, M., Witt, S.H., et al. Moderating role of FKBP5 genotype in the impact of childhood adversity on cortisol stress response during adulthood. Eur Neuropsychopharmacol 24 (2014), 837–845.
17. Fani, N., King, T.Z., Reiser, E., Binder, E.B., Jovanovic, T., Bradley, B., et al. FKBP5 genotype and structural integrity of the posterior cingulum. Neuropsychopharmacology 39 (2014), 1206–1213.
18. Höhne, N., Poidinger, M., Merz, F., Pfister, H., Bruckl, T., Zimmermann, P., et al. FKBP5 genotype-dependent DNA methylation and mRNA regulation after psychosocial stress in remitted depression and healthy controls. Int J Neuropsychopharmacol, 18(4), 2015, pyu087.
19. Ising, M., Depping, A.M., Siebertz, A., Lucae, S., Unschuld, P.G., Kloiber, S., et al. Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur J Neurosci 28 (2008), 389–398.
20. Luijk, M.P., Velders, F.P., Tharner, A., van Ijzendoorn, M.H., Bakermans-Kranenburg, M.J., Jaddoe, V.W., et al. FKBP5 and resistant attachment predict cortisol reactivity in infants: Gene-environment interaction. Psychoneuroendocrinology 35 (2010), 1454–1461.
21. Binder, E.B., Bradley, R.G., Liu, W., Epstein, M.P., Deveau, T.C., Mercer, K.B., et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 299 (2008), 1291–1305.
22. Touma, C., Gassen, N.C., Herrmann, L., Cheung-Flynn, J., Bull, D.R., Ionescu, I.A., et al. FK506 binding protein 5 shapes stress responsiveness: Modulation of neuroendocrine reactivity and coping behavior. Biol Psychiatry 70 (2011), 928–936.
23. Cordova-Palomera, A., de Reus, M.A., Fatjo-Vilas, M., Falcon, C., Bargallo, N., van den Heuvel, M.P., et al. FKBP5 modulates the hippocampal connectivity deficits in depression: A study in twins. Brain Imaging Behav 11 (2017), 62–75.
24. Wang, C., Shen, M., Guillaume, B., Chong, Y.S., Chen, H., Fortier, M.V., et al. FKBP5 moderates the association between antenatal maternal depressive symptoms and neonatal brain morphology. Neuropsychopharmacology 43 (2018), 564–570.
25. Wang, Q., Shelton, R.C., Dwivedi, Y., Interaction between early-life stress and FKBP5 gene variants in major depressive disorder and post-traumatic stress disorder: A systematic review and meta-analysis. J Affect Disord 225 (2018), 422–428.
26. Culverhouse, R.C., Saccone, N.L., Horton, A.C., Ma, Y., Anstey, K.J., Banaschewski, T., et al. Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. Mol Psychiatry 23 (2018), 133–142.
27. Ioannidis, J.P., Tarone, R., McLaughlin, J.K., The false-positive to false-negative ratio in epidemiologic studies. Epidemiology 22 (2011), 450–456.
28. Munafo, M.R., Understanding the candidate gene x environment interaction debate: Epistemological or evidential divide?. Int J Epidemiol 44 (2015), 1130–1132.
29. Dick, D.M., Agrawal, A., Keller, M.C., Adkins, A., Aliev, F., Monroe, S., et al. Candidate gene-environment interaction research: Reflections and recommendations. Perspect Psychol Sci 10 (2015), 37–59.
30. Fani, N., Gutman, D., Tone, E.B., Almli, L., Mercer, K.B., Davis, J., et al. FKBP5 and attention bias for threat: Associations with hippocampal function and shape. JAMA Psychiatry 70 (2013), 392–400.
31. Holz, N.E., Buchmann, A.F., Boecker, R., Blomeyer, D., Baumeister, S., Wolf, I., et al. Role of FKBP5 in emotion processing: Results on amygdala activity, connectivity and volume. Brain Struct Funct 220 (2015), 1355–1368.
32. Pagliaccio, D., Luby, J.L., Bogdan, R., Agrawal, A., Gaffrey, M.S., Belden, A.C., et al. Stress-system genes and life stress predict cortisol levels and amygdala and hippocampal volumes in children. Neuropsychopharmacology 39 (2014), 1245–1253.
33. Sullivan, P.F., Agrawal, A., Bulik, C.M., Andreassen, O.A., Borglum, A.D., Breen, G., et al. Psychiatric genomics: An update and an agenda. Am J Psychiatry 175 (2018), 15–27.
34. Cross-Disorder Group of the Psychiatric Genomics Consortium, Lee, S.H., Ripke, S., Neale, B.M., Faraone, S.V., Purcell, S.M., et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 45 (2013), 984–994.
35. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. Lancet 381 (2013), 1371–1379.
36. Cristobal-Narvaez, P., Sheinbaum, T., Myin-Germeys, I., Kwapil, T.R., de Castro-Catala, M., Dominguez-Martinez, T., et al. The role of stress-regulation genes in moderating the association of stress and daily-life psychotic experiences. Acta Psychiatr Scand 136 (2017), 389–399.
37. Lahti, J., Ala-Mikkula, H., Kajantie, E., Haljas, K., Eriksson, J.G., Raikkonen, K., Associations between self-reported and objectively recorded early life stress, FKBP5 polymorphisms, and depressive symptoms in midlife. Biol Psychiatry 80 (2016), 869–877.
38. Lieberman, R., Armeli, S., Scott, D.M., Kranzler, H.R., Tennen, H., Covault, J., FKBP5 genotype interacts with early life trauma to predict heavy drinking in college students. Am J Med Genet B Neuropsychiatr Genet 171 (2016), 879–887.
39. Hubler, T.R., Scammell, J.G., Intronic hormone response elements mediate regulation of FKBP5 by progestins and glucocorticoids. Cell Stress Chaperones 9 (2004), 243–252.
40. Paakinaho, V., Makkonen, H., Jaaskelainen, T., Palvimo, J.J., Glucocorticoid receptor activates poised FKBP51 locus through long-distance interactions. Mol Endocrinol 24 (2010), 511–525.
41. Klengel, T., Binder, E.B., Epigenetics of stress-related psychiatric disorders and gene x environment interactions. Neuron 86 (2015), 1343–1357.
42. Non, A.L., Hollister, B.M., Humphreys, K.L., Childebayeva, A., Esteves, K., Zeanah, C.H., et al. DNA methylation at stress-related genes is associated with exposure to early life institutionalization. Am J Phys Anthropol 161 (2016), 84–93.
43. Tyrka, A.R., Ridout, K.K., Parade, S.H., Paquette, A., Marsit, C.J., Seifer, R., Childhood maltreatment and methylation of FKBP5. Dev Psychopathol 27 (2015), 1637–1645.
44. Parade, S.H., Parent, J., Rabemananjara, K., Seifer, R., Marsit, C.J., Yang, B.Z., et al. Change in FK506 binding protein 5 (FKBP5) methylation over time among preschoolers with adversity. Dev Psychopathol 29 (2017), 1627–1634.
45. Ewald, E.R., Wand, G.S., Seifuddin, F., Yang, X., Tamashiro, K.L., Potash, J.B., et al. Alterations in DNA methylation of Fkbp5 as a determinant of blood-brain correlation of glucocorticoid exposure. Psychoneuroendocrinology 44 (2014), 112–122.
46. Lee, R.S., Tamashiro, K.L., Yang, X., Purcell, R.H., Harvey, A., Willour, V.L., et al. Chronic corticosterone exposure increases expression and decreases deoxyribonucleic acid methylation of Fkbp5 in mice. Endocrinology 151 (2010), 4332–4343.
47. Grange, T., Cappabianca, L., Flavin, M., Sassi, H., Thomassin, H., In vivo analysis of the model tyrosine aminotransferase gene reveals multiple sequential steps in glucocorticoid receptor action. Oncogene 20 (2001), 3028–3038.
48. Thomassin, H., Flavin, M., Espinas, M.L., Grange, T., Glucocorticoid-induced DNA demethylation and gene memory during development. EMBO J 20 (2001), 1974–1983.
49. Yehuda, R., Daskalakis, N.P., Bierer, L.M., Bader, H.N., Klengel, T., Holsboer, F., et al. Holocaust exposure induced intergenerational effects on FKBP5 methylation. Biol Psychiatry 80 (2016), 372–380.
50. Tozzi, L., Farrell, C., Booij, L., Doolin, K., Nemoda, Z., Szyf, M., et al. Epigenetic changes of FKBP5 as a link connecting genetic and environmental risk factors with structural and functional brain changes in major depression. Neuropsychopharmacology 43 (2018), 1138–1145.
51. Hertel, J., Konig, J., Homuth, G., Van der Auwera, S., Wittfeld, K., Pietzner, M., et al. Evidence for stress-like alterations in the HPA-axis in women taking oral contraceptives. Sci Rep, 7, 2017, 14111.
52. Shannon Weickert, C., Webster, M.J., Boerrigter, D., Sinclair, D., FKBP5 mRNA increases after adolescence in human DLPFC. Biol Psychiatry 80 (2016), e29–e31.
53. Blair, L.J., Nordhues, B.A., Hill, S.E., Scaglione, K.M., O'Leary, J.C. 3rd, Fontaine, S.N., et al. Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest 123 (2013), 4158–4169.
54. Sabbagh, J.J., O'Leary, J.C. 3rd, Blair, L.J., Klengel, T., Nordhues, B.A., Fontaine, S.N., et al. Age-associated epigenetic upregulation of the FKBP5 gene selectively impairs stress resiliency. PLoS One, 9, 2014, e107241.
55. Volk, N., Pape, J.C., Engel, M., Zannas, A.S., Cattane, N., Cattaneo, A., et al. Amygdalar microRNA-15a is essential for coping with chronic stress. Cell Rep 17 (2016), 1882–1891.
56. Zheng, D., Sabbagh, J.J., Blair, L.J., Darling, A.L., Wen, X., Dickey, C.A., MicroRNA-511 binds to FKBP5 mRNA, which encodes a chaperone protein, and regulates neuronal differentiation. J Biol Chem 291 (2016), 17897–17906.
57. White, M.G., Bogdan, R., Fisher, P.M., Munoz, K.E., Williamson, D.E., Hariri, A.R., FKBP5 and emotional neglect interact to predict individual differences in amygdala reactivity. Genes Brain Behav 11 (2012), 869–878.
58. Pagliaccio, D., Luby, J.L., Bogdan, R., Agrawal, A., Gaffrey, M.S., Belden, A.C., et al. Amygdala functional connectivity, HPA axis genetic variation, and life stress in children and relations to anxiety and emotion regulation. J Abnorm Psychol 124 (2015), 817–833.
59. Harms, M.B., Birn, R., Provencal, N., Wiechmann, T., Binder, E.B., Giakas, S.W., et al. Early life stress, FK506 binding protein 5 gene (FKBP5) methylation, and inhibition-related prefrontal function: A prospective longitudinal study. Dev Psychopathol 29 (2017), 1895–1903.
60. Hart, H., Lim, L., Mehta, M.A., Chatzieffraimidou, A., Curtis, C., Xu, X., et al. Reduced functional connectivity of fronto-parietal sustained attention networks in severe childhood abuse. PLoS One, 12, 2017, e0188744.
61. Hoeijmakers, L., Harbich, D., Schmid, B., Lucassen, P.J., Wagner, K.V., Schmidt, M.V., et al. Depletion of FKBP51 in female mice shapes HPA axis activity. PLoS One, 9, 2014, e95796.
62. Hartmann, J., Wagner, K.V., Liebl, C., Scharf, S.H., Wang, X.D., Wolf, M., et al. The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress. Neuropharmacology 62 (2012), 332–339.
63. Gaali, S., Kirschner, A., Cuboni, S., Hartmann, J., Kozany, C., Balsevich, G., et al. Selective inhibitors of the FK506-binding protein 51 by induced fit. Nat Chem Biol 11 (2015), 33–37.
64. Albu, S., Romanowski, C.P., Letizia Curzi, M., Jakubcakova, V., Flachskamm, C., Gassen, N.C., et al. Deficiency of FK506-binding protein (FKBP) 51 alters sleep architecture and recovery sleep responses to stress in mice. J Sleep Res 23 (2014), 176–185.
65. Attwood, B.K., Bourgognon, J.M., Patel, S., Mucha, M., Schiavon, E., Skrzypiec, A.E., et al. Neuropsin cleaves EphB2 in the amygdala to control anxiety. Nature 473 (2011), 372–375.
66. Hartmann, J., Wagner, K.V., Gaali, S., Kirschner, A., Kozany, C., Rühter, G., et al. Pharmacological inhibition of the psychiatric risk factor FKBP51 has anxiolytic properties. J Neurosci 35 (2015), 9007–9016.
67. Galatzer-Levy, I.R., Andero, R., Sawamura, T., Jovanovic, T., Papini, S., Ressler, K.J., et al. A cross species study of heterogeneity in fear extinction learning in relation to FKBP5 variation and expression: Implications for the acute treatment of posttraumatic stress disorder. Neuropharmacology 116 (2017), 188–195.
68. O'Leary, J.C. 3rd, Dharia, S., Blair, L.J., Brady, S., Johnson, A.G., Peters, M., et al. A new anti-depressive strategy for the elderly: Ablation of FKBP5/FKBP51. PLoS One, 6, 2011, e24840.
69. Sawamura, T., Klengel, T., Armario, A., Jovanovic, T., Norrholm, S.D., Ressler, K.J., et al. Dexamethasone treatment leads to enhanced fear extinction and dynamic Fkbp5 regulation in amygdala. Neuropsychopharmacology 41 (2016), 832–846.
70. Gaali, S., Gopalakrishnan, R., Wang, Y., Kozany, C., Hausch, F., The chemical biology of immunophilin ligands. Curr Med Chem 18 (2011), 5355–5379.
71. Tatro, E.T., Everall, I.P., Masliah, E., Hult, B.J., Lucero, G., Chana, G., et al. Differential expression of immunophilins FKBP51 and FKBP52 in the frontal cortex of HIV-infected patients with major depressive disorder. J Neuroimmune Pharmacol 4 (2009), 218–226.
72. Sinclair, D., Fillman, S.G., Webster, M.J., Weickert, C.S., Dysregulation of glucocorticoid receptor co-factors FKBP5, BAG1 and PTGES3 in prefrontal cortex in psychotic illness. Sci Rep, 3, 2013, 3539.
73. Chen, H., Wang, N., Zhao, X., Ross, C.A., O'Shea, K.S., McInnis, M.G., Gene expression alterations in bipolar disorder postmortem brains. Bipolar Disord 15 (2013), 177–187.
74. Darby, M.M., Yolken, R.H., Sabunciyan, S., Consistently altered expression of gene sets in postmortem brains of individuals with major psychiatric disorders. Transl Psychiatry, 6, 2016, e890.
75. Young, K.A., Thompson, P.M., Cruz, D.A., Williamson, D.E., Selemon, L.D., BA11 FKBP5 expression levels correlate with dendritic spine density in postmortem PTSD and controls. Neurobiol Stress 2 (2015), 67–72.
76. Patel, N., Crider, A., Pandya, C.D., Ahmed, A.O., Pillai, A., Altered mRNA levels of glucocorticoid receptor, mineralocorticoid receptor, and co-chaperones (FKBP5 and PTGES3) in the middle frontal gyrus of autism spectrum disorder subjects. Mol Neurobiol 53 (2016), 2090–2099.
77. Mamdani, F., Rollins, B., Morgan, L., Myers, R.M., Barchas, J.D., Schatzberg, A.F., et al. Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder. Transl Psychiatry, 5, 2015, e636.
78. Pérez-Ortiz, J.M., García-Gutiérrez, M.S., Navarrete, F., Giner, S., Manzanares, J., Gene and protein alterations of FKBP5 and glucocorticoid receptor in the amygdala of suicide victims. Psychoneuroendocrinology 38 (2013), 1251–1258.
79. Balsevich, G., Uribe, A., Wagner, K.V., Hartmann, J., Santarelli, S., Labermaier, C., et al. Interplay between diet-induced obesity and chronic stress in mice: Potential role of FKBP51. J Endocrinol 222 (2014), 15–26.
80. Pereira, M.J., Palming, J., Svensson, M.K., Rizell, M., Dalenback, J., Hammar, M., et al. FKBP5 expression in human adipose tissue increases following dexamethasone exposure and is associated with insulin resistance. Metabolism 63 (2014), 1198–1208.
81. Balsevich, G., Hausl, A.S., Meyer, C.W., Karamihalev, S., Feng, X., Pohlmann, M.L., et al. Stress-responsive FKBP51 regulates AKT2-AS160 signaling and metabolic function. Nat Commun, 8, 2017, 1725.
82. Maiaru, M., Tochiki, K.K., Cox, M.B., Annan, L.V., Bell, C.G., Feng, X., et al. The stress regulator FKBP51 drives chronic pain by modulating spinal glucocorticoid signaling. Sci Transl Med, 8, 2016, 325ra319.
83. Lieberman, R., Kranzler, H.R., Levine, E.S., Covault, J., Examining FKBP5 mRNA expression in human iPSC-derived neural cells. Psychiatry Res 247 (2017), 172–181.
84. Lein, E.S., Hawrylycz, M.J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445 (2006), 168–176.
85. Thul, P.J., Åkesson, L., Wiking, M., Mahdessian, D., Geladaki, A., Blal, H.A., et al. A subcellular map of the human proteome. Science, 356(6340), 2017.
86. Soontornniyomkij, V., Everall, I.P., Moore, D.J., Gouaux, B., Tatro, E.T., Gospodarev, V., et al. Increased cortical expression of FK506 binding protein-51 in HIV-associated neurocognitive disorders. J Neurovirol 18 (2012), 313–322.
87. Avramut, M., Immunophilins: New Biomarkers and Therapeutic Targets for Neurodegenerative Diseases. [dissertation], 2003, University of Pittsburgh, Pittsburgh.
88. Young, J.C., Obermann, W.M.J., Hartl, F.U., Specific binding of tetratricopeptide repeat proteins to the C-terminal 12-kDa domain of hsp90. Biol Chem 273 (1998), 18007–18010.
89. Fabian, A.K., März, A., Neimanis, S., Biondi, R.M., Kozany, C., Hausch, F., InterAKTions with FKBPs—mutational and pharmacological exploration. PLoS One, 8, 2013, e57508.
90. Baughman, G., Wiederrecht, G.J., Campbell, N.F., Martin, M.M., Bourgeois, S., FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. Mol Cell Biol 15 (1995), 4395–4402.
91. Weiwad, M., Edlich, F., Kilka, S., Erdmann, F., Jarczowski, F., Dorn, M., et al. Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins. Biochemistry 45 (2006), 15776–15784.
92. Li, W., Handschumacher, R.E., Identification of two calcineurin B-binding proteins: Tubulin and heat shock protein 60. Biochim Biophys Acta 1599 (2002), 72–81.
93. Baumgartel, K., Mansuy, I.M., Neural functions of calcineurin in synaptic plasticity and memory. Learn Mem 19 (2012), 375–384.
94. Almeida-Correa, S., Moulin, T.C., Carneiro, C.F., Goncalves, M.M., Junqueira, L.S., Amaral, O.B., Calcineurin inhibition blocks within-, but not between-session fear extinction in mice. Learn Mem 22 (2015), 159–169.
95. de la Fuente, V., Federman, N., Fustinana, M.S., Zalcman, G., Romano, A., Calcineurin phosphatase as a negative regulator of fear memory in hippocampus: Control on nuclear factor-kappaB signaling in consolidation and reconsolidation. Hippocampus 24 (2014), 1549–1561.
96. Shaw, J.A., Matlovich, N., Rushlow, W., Cain, P., Rajakumar, N., Role of calcineurin in inhibiting disadvantageous associations. Neuroscience 203 (2012), 144–152.
97. Bouwmeester, T., Bauch, A., Ruffner, H., Angrand, P.O., Bergamini, G., Croughton, K., et al. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol 6 (2004), 97–105.
98. Romano, M.F., Avellino, R., Petrella, A., Bisogni, R., Romano, S., Venuta, S., Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 40 (2004), 2829–2836.
99. Romano, S., Staibano, S., Greco, A., Brunetti, A., Nappo, G., Ilardi, G., et al. FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential. Cell Death Dis, 4, 2013, e578.
100. Kaltschmidt, C., Kaltschmidt, B., Neumann, H., Wekerle, H., Baeuerle, P.A., Constitutive NF-kappa B activity in neurons. Mol Cell Biol 14 (1994), 3981–3992.
101. Frensing, T., Kaltschmidt, C., Schmitt-John, T., Characterization of a neuregulin-1 gene promoter: Positive regulation of type I isoforms by NF-κB. Biochim Biophys Acta 1779 (2008), 139–144.
102. Rao, J.S., Harry, G.J., Rapoport, S.I., Kim, H.W., Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 15 (2010), 384–392.
103. Naik, U.S., Gangadharan, C., Abbagani, K., Nagalla, B., Dasari, N., Manna, S.K., A study of nuclear transcription factor-kappa B in childhood autism. PLoS One, 6, 2011, e19488.
104. Song, X.Q., Lv, L.X., Li, W.Q., Hao, Y.H., Zhao, J.P., The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry 65 (2009), 481–488.
105. Hou, J., Wang, L., FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer. PLoS One, 7, 2012, e36252.
106. Pei, H., Li, L., Fridley, B.L., Jenkins, G.D., Kalari, K.R., Lingle, W., et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 16 (2009), 259–266.
107. Kollmannsberger LK (2016): The Role of FKBP5 in Transcriptional Regulation and in Shaping Cellular Pathways of Psychopharmaca Action [dissertation]. Munich: LMU München: Faculty of Chemistry and Pharmacy.
108. Gassen, N.C., Hartmann, J., Schmidt, M.V., Rein, T., FKBP5/FKBP51 enhances autophagy to synergize with antidepressant action. Autophagy 11 (2015), 578–580.
109. Cohen, P., Frame, S., The renaissance of GSK3. Nat Rev Mol Cell Biol 2 (2001), 769–776.
110. Hur, E.M., Zhou, F.Q., GSK3 signalling in neural development. Nat Rev Neurosci 11 (2010), 539–551.
111. Harwood, A.J., Regulation of GSK-3: A cellular multiprocessor. Cell 105 (2001), 821–824.
112. Gassen, N.C., Hartmann, J., Zannas, A.S., Kretzschmar, A., Zschocke, J., Maccarrone, G., et al. FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications. Mol Psychiatry 21 (2016), 277–289.
113. Sun, Y., Liu, W.Z., Liu, T., Feng, X., Yang, N., Zhou, H.F., Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res 35 (2015), 600–604.
114. Lavoie, G., St-Pierre, Y., Phosphorylation of human DNMT1: Implication of cyclin-dependent kinases. Biochem Biophys Res Commun 409 (2011), 187–192.
115. Gassen, N.C., Fries, G.R., Zannas, A.S., Hartmann, J., Zschocke, J., Hafner, K., et al. Chaperoning epigenetics: FKBP51 decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant paroxetine. Sci Signal, 8, 2015, ra119.
116. Boulle, F., van den Hove, D.L., Jakob, S.B., Rutten, B.P., Hamon, M., van Os, J., et al. Epigenetic regulation of the BDNF gene: implications for psychiatric disorders. Mol Psychiatry 17 (2012), 584–596.
117. Gallo, L.I., Lagadari, M., Piwien-Pilipuk, G., Galigniana, M.D., The 90-kDa heat-shock protein (Hsp90)-binding immunophilin FKBP51 is a mitochondrial protein that translocates to the nucleus to protect cells against oxidative stress. J Biol Chem 286 (2011), 30152–30160.
118. Toneatto, J., Guber, S., Charo, N.L., Susperreguy, S., Schwartz, J., Galigniana, M.D., et al. Dynamic mitochondrial-nuclear redistribution of the immunophilin FKBP51 is regulated by the PKA signaling pathway to control gene expression during adipocyte differentiation. J Cell Sci 126 (2013), 5357–5368.
119. Akiyama, T., Shiraishi, T., Qin, J., Konno, H., Akiyama, N., Shinzawa, M., et al. Mitochondria-nucleus shuttling FK506-binding protein 51 interacts with TRAF proteins and facilitates the RIG-I-like receptor-mediated expression of type I IFN. PLoS One, 9, 2014, e95992.
120. Schiavone, S., Jaquet, V., Trabace, L., Krause, K.H., Severe life stress and oxidative stress in the brain: From animal models to human pathology. Antioxid Redox Signal 18 (2013), 1475–1490.
121. Holmes, S.E., Girgenti, M.J., Davis, M.T., Pietrzak, R.H., DellaGioia, N., Nabulsi, N., et al. Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence. Proc Natl Acad Sci U S A 114 (2017), 8390–8395.